BEDMINSTER, N.J. (AP) — BEDMINSTER, N.J. (AP) — Intra-Cellular Therapies Inc. (ITCI) on Friday reported a loss of $16.9 million in its fourth quarter.
On a per-share basis, the Bedminster, New Jersey-based company said it had a loss of 16 cents.
The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 5 cents per share.
The biopharmaceutical company posted revenue of $199.2 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $192.9 million.
For the year, the company reported a loss of $74.7 million, or 72 cents per share. Revenue was reported as $680.9 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ITCI at https://www.zacks.com/ap/ITCI
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。